NASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical...
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release...
TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical...
LDN+ Drug Designed to Combat PTSD and Suicidal IdeationJACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation...
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum...
ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials...
Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safetyVANCOUVER,...
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita® in patients with...
Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) --...
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline...
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions...
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused...
– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data...
– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –...
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through...
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects,...
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,...
Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related...
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025WOODCLIFF LAKE, N.J., April 30,...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...